Sources: 1BitterDB, 4ClinicalTrials, 7Cochrane Library, 10DGIdb, 14DrugBank, 29HMDB, 33IUPHAR, 46NDF-RT, 50Novoseek, 56PharmGKB, 68UMLSSee all MalaCards sources |
Drugs for Diffuse Scleroderma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB): (show top 50)
(show all 253)
| id | | Name | Status | Phase | Clinical Trials | Cas Number | PubChem Id |
|---|
| 1 | | Tadalafil | approved, investigational | Phase 4, Phase 3, Phase 2 | 155 | 171596-29-5 | 110635 | (6R,12AR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione (6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione 171596-29-5 1xoz 6-BENZO[1,3]dioxol-5-yl-2-methyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione AC1L380B ADCIRCA Acdirca Adcirca C429886 CHEBI:41488 CHEMBL779 CID110635 CPD000466321 Cialis Cialis (TN) Cialis, GF 196960, IC 351, ICOS 351, Tadalafil D02008 DB00820 FT-0080116 GF 196960 GF-196960 | HMS2051N17 HSDB 7303 IC 351 IC-351 ICOS 351 Ic351 KS-1117 LS-186558 LS-187015 LS-187770 Lilly brand of tadalafil MLS000759426 MLS001165782 MLS001195644 MLS001424132 MolPort-002-885-864 S1512_Selleck SAM001246586 SMR000466321 Tadalafil Tadalafil (JAN/USAN/INN) Tadalafil [USAN] Tadanafil UNII-742SXX0ICT ZINC03993855 | |
| | 2 | | Bosentan | approved, investigational | Phase 4, Phase 3, Phase 2, Phase 1 | 104 | 147536-97-8 | 104865 | -5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]benzenesulfonamide 147536-97-8 174227-18-0 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl)benzenesulfornamide 4-t-butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulfonamide 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide AC-148 AC1L2XN2 Actelion Bosentan Bosentan (INN) Bosentan [USAN:INN:BAN] Bosentan hydrate C27H29N5O6S CHEBI:51450 CHEMBL957 CID104865 D07538 DB00559 | EN002863 HMS2090N14 I06-1873 KS-5062 L001086 LS-31532 MolPort-003-845-300 NCGC00167440-01 PDSP1_001731 PDSP2_001714 Ro 47-0203 Ro 47-0203/039 Ro-47-0203 Ro-47-0203/029 Ro-47-0203/039 TL8001039 Tracleer UNII-XUL93R30K2 bosentan bosentanum bosentán p-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide p-tert-Butyl-N-[6-(2-hydroxyethoxy) |
| | 3 | | Cilostazol | approved | Phase 4 | 106 | 73963-72-1 | 2754 | 3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone 3,4-dihydro-6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxyl)-3,4-dihydrocarobostyril 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one 73963-72-1 89332-50-3 AC-4334 AC1L1EE2 BRD-K67017579-001-04-2 BRD-K67017579-001-05-9 BRD-K67017579-001-07-5 BRD-K67017579-001-13-3 BRN 3632107 BSPBio_002759 C 0737 C045645 C0737_SIGMA C20H27N5O2 CHEBI:31401 CHEMBL799 CID2754 CL23867 CPD000058428 Cilostazol (JP15/USAN/INN) Cilostazol [INN:JAN] Cilostazole Cilostazolum Cilostazolum [INN-Latin] D01896 DB01166 EU-0100218 HMS1922N15 HMS2093M14 KBio3_002259 KBioGR_001184 | LS-142693 Lopac-C-0737 Lopac0_000218 MLS000028470 MLS000758281 MLS000759507 MLS001076067 MLS002153891 MolPort-001-758-007 NCGC00015207-01 NCGC00015207-02 NCGC00015207-06 NCGC00015207-10 NCGC00022153-02 NCGC00022153-04 NCGC00022153-05 NCGC00022153-06 NCGC00022153-07 OPC 13013 OPC 21 OPC-13013 OPC-21 Otsuka brand of cilostazol Pletaal Pletal Pletal (TN) Pletal, Cilostazol S1294_Selleck SAM001246734 SAM001247085 SMR000058428 SPBio_001256 SPECTRUM1505230 Spectrum2_001118 Spectrum3_001170 Spectrum4_000772 Spectrum5_001762 TL8005113 Tocris-1692 UNII-N7Z035406B ZINC01552174 cilostazol |
| | 4 | | Platelet Aggregation Inhibitors | | Phase 4, Phase 2, Phase 3 | 2516 | | | | 5 | | Peripheral Nervous System Agents | | Phase 4, Phase 2, Phase 3, Phase 1, Early Phase 1 | 23689 | | | | 6 | | Protective Agents | | Phase 4, Phase 2, Phase 3, Phase 1, Early Phase 1 | 7443 | | | | 7 | | Respiratory System Agents | | Phase 4, Phase 2, Phase 3 | 4997 | | | | 8 | | Vaccines | | Phase 4 | 6611 | | | | 9 | | Sildenafil Citrate | | Phase 4, Phase 3, Phase 2, Early Phase 1 | 331 | 171599-83-0 | | | 10 | | Endothelin Receptor Antagonists | | Phase 4, Phase 3, Phase 2, Phase 1 | 218 | | | | 11 | | Neuroprotective Agents | | Phase 4, Phase 2, Phase 3, Early Phase 1 | 1716 | | | | 12 | | Phosphodiesterase Inhibitors | | Phase 4, Phase 3, Phase 2, Early Phase 1 | 1289 | | | | 13 | | Phosphodiesterase 5 Inhibitors | | Phase 4, Phase 3, Phase 2, Early Phase 1 | 589 | | | | 14 | | Antihypertensive Agents | | Phase 4, Phase 3, Phase 2, Phase 1 | 4207 | | | | 15 | | Vasodilator Agents | | Phase 4, Phase 2, Phase 3, Early Phase 1 | 3543 | | | | 16 | | Autonomic Agents | | Phase 4, Phase 3, Phase 2, Early Phase 1 | 10150 | | | | 17 | | Phosphodiesterase 3 Inhibitors | | Phase 4 | 133 | | | | 18 | | Fibrinolytic Agents | | Phase 4, Phase 2, Phase 3 | 2388 | | | | 19 | | Bronchodilator Agents | | Phase 4 | 2965 | | | | 20 | | Anti-Asthmatic Agents | | Phase 4 | 3488 | | | | 21 | | Liver Extracts | | Phase 4 | 4067 | | | | 22 | | Citrate | Nutraceutical | Phase 4, Phase 3, Phase 2, Early Phase 1 | 1160 | | | | 23 | | Acidophilus | Nutraceutical | Phase 4, Phase 3 | 558 | | | | 24 | | Citric Acid | nutraceutical, vet_approved | Phase 4, Phase 3, Phase 2, Early Phase 1 | 1160 | 77-92-9 | 311 | 2-Hydroxy-1,2,3-propanetricarboxylate 2-Hydroxy-1,2,3-propanetricarboxylic acid 2-Hydroxytricarballylic acid 3-Carboxy-3-hydroxypentane-1,5-dioate 3-Carboxy-3-hydroxypentane-1,5-dioic acid Aciletten Anhydrous citrate Anhydrous citric acid Chemfill Citraclean | Citrate Citretten Citric acid Citro Citronensäure E 330 Hydrocerol A Kyselina citronova Suby G Uro-trainer beta-Hydroxytricarballylate beta-Hydroxytricarballylic acid |
| | 25 | | Omega 3 Fatty Acid | Nutraceutical | Phase 4 | 1018 | | | | 26 | | Acetylcysteine | approved, investigational | Phase 2, Phase 3 | 330 | 616-91-1 | 12035 | (2R)-2-acetylamino-3-sulfanylpropanoic acid (R)-2-acetylamino-3-mercaptopropanoic acid (R)-mercapturic acid 2-Acetylamino-3-mercapto-propionate 2-Acetylamino-3-mercapto-propionic acid ACC Acetadote Acetilcisteina Acetylcysteine Acetylcysteinum Fluimicil Infantil Fluimucetin Fluimucil Flumucetin Fluprowit | L-Acetylcysteine L-acetylcysteine L-α-acetamido-β-mercaptopropionic acid Lysox Mercapturic acid Mucolysin Mucomyst N-Acety-L-Cysteine N-Acetyl-3-mercaptoalanine N-Acetyl-L-(+)-cysteine N-Acetylcysteine N-acetyl-L-(+)-cysteine N-acetyl-L-cysteine N-acetylcysteine NAC Parvolex Sodium 2-acetamido-3-mercaptopropionate |
| | 27 | | Prednisolone | approved, vet_approved | Phase 2, Phase 3, Early Phase 1 | 1193 | 50-24-8 | 5755 | (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione .DELTA.1-Cortisol .DELTA.1-Dehydrocortisol .DELTA.1-Dehydrohydrocortisone .DELTA.1-Hydrocortisone .delta.-Cortef .delta.-Stab 1,2-Dehydrohydrocortisone 1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione 1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol 1-Dehydrocortisol 1-Dehydrohydrocortisone 3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene 46656_FLUKA 46656_RIEDEL 50-24-8 58201-11-9 8056-11-9 AC-1773 AC1L1L2E Ak-Pred Ak-Tate Alphadrol Articulose-50 BPBio1_000164 BRD-K98039984-001-03-0 BRN 1354103 BSPBio_000148 Bio-0666 Bubbli-Pred C07369 CCRIS 980 CHEBI:8378 CHEMBL131 CID5755 CO-Hydeltra CPD000718761 Co-Hydeltra Codelcortone Cordrol Cortalone Cotogesic Cotolone D00472 D011239 DB00860 Decaprednil Decortin H Delcortol Delta F Delta(1)-dehydrohydrocortisone Delta-Cortef Delta-Cortef (TN) Delta-Ef-Cortelan Delta-Stab Delta-stab Deltacortenol Deltacortril Deltacortril Enteric Deltahydrocortisone Deltasolone Deltisilone Depo-Medrol Derpo PD Derpo Pd Dexa-Cortidelt Hostacortin H Dexa-Cortidelt hostacortin H Di Adreson F Di-Adreson F Di-Adreson-F Di-adreson F DiAdresonF Dicortol Donisolone Dydeltrone EINECS 200-021-7 Eazolin D Econopred Econopred Plus Erbacort Erbasona Estilsona Fernisolone Fernisolone P Fernisolone-P Flamasone HMS1568H10 HMS2090J05 HSDB 3385 Hostacortin H Hydeltra Hydeltra-Tba Hydeltrasol Hydeltrone Hydrodeltalone Hydrodeltisone Hydroretrocortin Hydroretrocortine I-Pred Inflamase Forte Inflamase Mild K 1557 Key-Pred Klismacort LMST02030179 LS-7669 Lentosone Lite Pred M-Predrol | MLS001304083 MLS002154250 MLS002207037 Medrol Medrol Acetate Metacortandralone Methylprednisolone Acetate Meti-Derm Meticortelone Metreton MolPort-002-507-147 NCGC00179649-01 NSC 9120 NSC9120 NSC9900 Neo-Delta-Cortef Nisolone Nor-Pred T.B.A. Ocu-Pred Ocu-Pred Forte Ophtho-Tate Orapred P0152_SIGMA P0637 P6004_SIGMA PRDL PRED-G Panafcortelone Paracortol Paracotol Pediapred Poly-Pred Precortalon Precortancyl Precortilon Precortisyl Pred Forte Pred Mild Predair Predair A Predair Forte Predalone 50 Predalone T.B.A. Predate Predate Tba Predate-50 Predcor-25 Predcor-50 Predcor-Tba Predisolone Sodium Phosphate Predne-Dome Prednelan Predni-Dome Prednicen Predniliderm Predniretard Prednis Prednisolona Prednisolona [INN-Spanish] Prednisolone (JP15/USP/INN) Prednisolone (anhydrous) Prednisolone Acetate Prednisolone Sodium Phosphate Prednisolone Tebutate Prednisolone [INN:BAN:JAN] Prednisolonum Prednisolonum [INN-Latin] Predonin Predonine Prelone Prenolone Prestwick0_000274 Prestwick1_000274 Prestwick2_000274 Prestwick3_000274 Prestwick_404 Rolisone S1737_Selleck SAM002264639 SMR000718761 SPBio_002367 Scherisolon Solone Steran Sterane Sterolone Supercortisol UNII-9PHQ9Y1OLM Ulacort Ultra Pred Ultracorten H Ultracortene H Ultracortene-H Ultracortene-Hydrogen Ultracortene-hydrogen ZINC03833821 component of Ataraxoid component of K-Predne-Dome delta(1)-Cortisol delta(1)-Dehydrocortisol delta(1)-Dehydrohydrocortisone delta(1)-Hydrocortisone delta(sup 1)-Cortisol delta(sup 1)-Dehydrocortisol delta(sup 1)-Dehydrohydrocortisone delta(sup 1)-Hydrocortisone delta-dehydrocortisol delta-dehydrohydrocortisone delta-hydrocortisone prednisolone | |
| | 28 | | Methylprednisolone | approved, vet_approved | Phase 2, Phase 3, Early Phase 1 | 1193 | 83-43-2 | 6741 | (6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one (6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione (6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione (6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione .DELTA.1-6.alpha.-Methylhydrocortisone 1-Dehydro-6alpha-methylhydrocortisone 1-dehydro-6alpha-Methylhydrocortisone 1-dehydro-6α-methylhydrocortisone 11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione 11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione 11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione 11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione 121673-01-6 4-08-00-03498 (Beilstein Handbook Reference) 46436_FLUKA 46436_RIEDEL 570-35-4 6 Methylprednisolone 6-Methylprednisolone 6-alpha-Methylprednisolone 6.alpha.-Methylprednisolone 6923-42-8 6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione 6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione 6alpha-Methylprednisolone 6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione 83-43-2 AC1L1N7A Artisone-Wyeth Artisone-wyeth BPBio1_000174 BRD-K35240538-001-03-1 BRN 2340300 BSPBio_000158 Besonia Bio-0658 CHEBI:6888 CHEMBL650 CID6741 CPD000058330 D00407 D008775 DB00959 Depo-Medrol (acetate) Dopomedrol EINECS 201-476-4 Esametone Firmacort HMS1568H20 HMS2090B13 HSDB 3127 LMST02030178 LS-118498 Lemod M0639_SIGMA M1665 MEPRDL MLS000028541 MLS001148159 MLS002207191 Medesone Medixon Medlone 21 | Medrate Medrol Medrol (TN) Medrol Adt Pak Medrol Dosepak Medrol adt pak Medrol dosepak Medrol, Solu-Medrol, Medrone, Methylprednisolone Medrone Mesopren Metastab Methyleneprednisolone Methylprednisolon Methylprednisolone Methylprednisolone (JP15/USP/INN) Methylprednisolone [USAN:INN:BAN:JAN] Methylprednisolone, 6-alpha Methylprednisolonum Methylprednisolonum [INN-Latin] Metilbetasone Metilprednisolona Metilprednisolona [INN-Spanish] Metilprednisolone Metilprednisolone [DCIT] Metilprednisolone [Dcit] Metipred Metrisone Metrocort Metysolon Moderin MolPort-002-528-554 NCGC00022735-03 NCI60_001657 NSC-19987 NSC19987 Nirypan Noretona Predni N Tablinen Prednol- L Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI) Prestwick0_000279 Prestwick1_000279 Prestwick2_000279 Prestwick3_000279 Prestwick_622 Promacortine Reactenol S1733_Selleck SAM002589984 SMR000058330 SPBio_002377 Sieropresol Solomet Summicort Suprametil U 7532 UNII-X4W7ZR7023 Urbason Urbasone Wyacort ZINC03875560 delta(1)-6alpha-Methylhydrocortisone delta(sup 1)-6-alpha-Methylhydrocortisone methylprednisolone methylprenisolone |
| | 29 | | Cyclophosphamide | approved, investigational | Phase 3, Phase 2, Phase 1 | 2935 | 50-18-0, 6055-19-2 | 2907 | (+-)-Cyclophosphamide (-)-Cyclophosphamide (RS)-Cyclophosphamide 1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin 2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide 4-Hydroxy-cyclophosphan-mamophosphatide 50-18-0 60007-95-6 6055-19-2 (monohydrate) 75526-90-8 AC1L1EQQ AI3-26198 ASTA ASTA B518 Anhydrous cyclophosphamide Asta B 518 B 518 B-518 BRN 0011744 BSPBio_002099 Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester C 0768 C07888 C7H15Cl2N2O2P CB 4564 CB-4564 CCRIS 188 CHEBI:4027 CHEMBL32520 CHEMBL88 CID2907 CP CPA CTX CY Ciclofosfamida Ciclofosfamida [INN-Spanish] Ciclofosfamide Ciclophosphamide Ciclophosphamide [INN] Clafen Claphene Cycloblastin Cyclophosphamid Cyclophosphamide Cyclophosphamide (INN) Cyclophosphamide (TN) Cyclophosphamide (anhydrous form) Cyclophosphamide (anhydrous) Cyclophosphamide Monohydrate Cyclophosphamide Sterile Cyclophosphamide anhydrous Cyclophosphamide, (+-)-Isomer Cyclophosphamides Cyclophosphamidum Cyclophosphamidum [INN-Latin] Cyclophosphan Cyclophosphane Cyclophosphanum Cyclophosphoramide Cyclostin Cyklofosfamid Cyklofosfamid [Czech] Cytophosphan Cytophosphane Cytoxan Cytoxan (TN) Cytoxan Lyoph D,L-Cyclophosphamide D07760 | DB00531 DivK1c_000246 EINECS 200-015-4 EU-0100238 Endoxan Endoxan R Endoxan-Asta Endoxana Endoxanal Endoxane Enduxan Genoxal HMS2090A12 HSDB 3047 Hexadrin IDI1_000246 KBio1_000246 KBio2_001338 KBio2_003906 KBio2_006474 KBio3_001319 KBioGR_000888 KBioSS_001338 LS-1302 LS-99787 Ledoxina Lopac-C-0768 Lopac0_000238 Lyophilized Cytoxan Mitoxan MolPort-001-783-420 N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide NCGC00015209-01 NCGC00015209-03 NCGC00015209-06 NCGC00091741-02 NCGC00091741-03 NCI-C04900 NCI60_002097 NINDS_000246 NSC 26271 NSC-26271 NSC26271 NSC273033 NSC273034 Neosar Occupation, cyclophosphamide exposure Procytox RCRA waste no. U058 Rcra Waste Number U058 Rcra waste number U058 Revimmune S1217_Selleck SK 20501 SPBio_001071 STK177249 STOCK2S-91217 Semdoxan Sendoxan Senduxan Spectrum2_001146 Spectrum3_000370 Spectrum4_000304 Spectrum5_000795 Spectrum_000858 UNII-6UXW23996M WLN: T6MPOTJ BO BN2G2G Zyklophosphamid Zyklophosphamid [German] bis(2-Chloroethyl)phosphami de cyclic propanolamide bis(2-Chloroethyl)phosphamide cyclic propanolamide ester cyclophosphamide |
| | 30 | | Iloprost | approved, investigational | Phase 2, Phase 3 | 79 | 78919-13-8 | 6443959 | (16R,S)-Methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I(sub 2) (5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid (5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1H)-ylidene]pentanoic acid (5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid (5Z)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid (E)-(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-delta(sup 2(1H),delta)-pentalenevaleric acid (E)-5-(3aS,4R,5R,6aS)-5-Hydroxy-4((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-inyl)perhydropentalen-2-yliden)valeriansaeure 73873-87-7 78919-13-8 AC1NSK5T AC1O5JIJ AC1O5JP3 AC1Q1J28 ACT-213105 C22H32O4 CHEMBL138694 CHEMBL236025 CHEMBL494 CID10937300 CID11639089 CID5311181 CID6435293 CID6435378 CID9885245 | CID9975807 Ciloprost D02721 E-1030 Endoprost HMS2090A19 ILOPROST Ilomedin Ilomedine Iloprost Iloprost (INN) Iloprost [BAN:INN] Iloprostum Iloprostum [Latin] L000996 LS-101845 NCGC00181784-01 PDSP2_001536 SH-401 UNII-JED5K35YGL Ventavis Ventavis (TN) ZK 36374 ZK-36374 ZK-363775 [3H]-Iloprost |
| | 31 | | Nitroglycerin | approved, investigational | Phase 3, Phase 2 | 156 | 55-63-0 | 4510 | 1,2,3-Propanetrioltrinitrate 1,2,3-Propanetriyl nitrate 100292-13-5 105469-31-6 55-63-0 80066-48-4 8013-23-8 9010-02-0 AC1L1IBV Adesitrin Aldonitrin Angibid Angiolingual Angiplex Anglix Angonist Angorin Anogesic Aquo-Trimitrosan BIDD:GT0142 BRN 1802063 Blasting gelatin Blasting oil Buccal Buccard C07455 C3H5N3O9 CCRIS 4089 CHEBI:28787 CHEMBL730 CID4510 CPD-143 Cardabid Cardamist Cardinit Cardiodisco Cellegesic Chitamite Colenitral Cordipatch Corditrine Coro-Nitro D00515 D005996 DB00727 Dauxona Deponit Deponit 5 Deponit TTS 10 Deponit TTS 5 Deponit-5 Diafusor Discotrine Dynamite EINECS 200-240-8 Epinitril GTN GTN-Pohl Gepan Nitroglicerin Gilucor nitro Gilustenon Glonoin Glycerin trinitrate Glycerine trinitrate Glycerintrinitrate Glycerol trinitrate Glycerol, nitric acid triester Glyceroli trinitratis Glyceroltrinitraat Glyceroltrinitrat Glyceryl Glyceryl nitrate Glyceryl trinitrate Glycerylnitrat Glytrin HMS2094M15 HSDB 30 Herwicard Herzer IMX-150 Klavikordal LS-7741 Lenitral Lentonitrina MED-2002 MQX-503 Mi-Trates Millisrol Minitram Minitran Minitran (TN) Minitro Mionitrat Myocon Myoglycerin Myovin NG NITRO IV NK-843 NTG Natispray Neos nitro OPT Niglin Niglycon Niong Niong Retard Nirmin Nit-Ret Nitora Nitradisc Nitradisc Pad Nitradisc TTS Nitrangin Nitrek Nitriderm Nitriderm TTS Nitrine-TDC Nitro Bid Nitro Dur Nitro Dur TTS Nitro Mack Retard Nitro Retard Nitro Rorer Nitro-Bid Nitro-Dur 10 Nitro-Dur 5 Nitro-Gesanit Retard Nitro-M-Bid Nitro-Mack Retard Nitro-Par Nitro-Pflaster Nitro-Span Nitro-Time Nitro-bid (TN) Nitro-dur Nitro-dur (TN) Nitro-lent NitroBid NitroCor | NitroDur NitroMist NitroQuick NitroQuik Nitroard Nitrobaat Nitrobid Oint Nitrobukal Nitrocap NitrocapT.D NitrocapT.D. Nitrocard Nitrocerin Nitrocine Nitrocine 5 Nitroclyn Nitrocontin Nitrocontin Continus Nitrocot Nitroderm Nitroderm TTS Nitroderm TTS Ext Nitroderm TTS-5 Nitrodisc Nitrodyl Nitrodyl TTS Nitrogard Nitrogard-SR Nitroglicerina Nitrogliceryna Nitroglin Nitroglycerin Nitroglycerin (NG) Nitroglycerin ointment Nitroglycerin-ACC Nitroglycerine Nitroglycerol Nitroglyn Nitroject Nitrol Ointment Nitrolan Nitroletten Nitrolin Nitrolingual Nitrolingual Spray Nitrolowe Nitromack Retard Nitromed Nitromel Nitromex Nitromint Nitromint Aerosol Nitromint Retard Nitromist Nitromist (TN) Nitronal Aqueous Nitronet Nitrong Nitrong Retard Nitrong parenteral Nitrong-SR Nitropatch Nitropen Nitropercuten Nitroperlinit Nitroplast Nitroprol Nitropront Nitroprontan Nitrorectal Nitroretard Nitrorex Nitrospan Nitrostabilin Nitrostat Nitrovis Nitrozell retard Nysconitrine Percutol Percutol Oint Percutol Oint. Perganit Perglottal Perlinganit Plastranit Polnitrin Propane-1,2,3-triyl trinitrate RCRA waste no. P081 Ratiopharm Rectogesic SDM No. 17 SK-106N SK-866 SK-878 Soup Spirit of glonoin Susadrin Suscard Sustac Sustak Sustonit TNG Temponitrin Top-Nitro Transderm Nitro Transderm nitro Transderm-N TTS Transderm-Nitro TTS Transderm-nitro Transderm-nitro (TN) Transiderm-nitro Tridil Tridil sublin Trinalgon Trinipatch Triniplas Trinitrate, Glyceryl Trinitrin Trinitrin Tablets Trinitrina Erba Trinitrine Trinitroglycerin Trinitroglycerol Trinitrol Trinitrolong Trinitron Trinitrosan Turicard UN0143 UN0144 UN1204 UN3064 UN3319 UNII-G59M7S0WS3 Vascana Vasoglyn Vasolator Vernies Willong c0061 nitroglycerin |
| | 32 | | Mycophenolate mofetil | approved, investigational | Phase 3, Phase 2, Phase 1 | 952 | 128794-94-5 | 5281078 | 115007-34-6 128794-94-5 140401-05-4 2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate 2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate 2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate 2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate 2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E) AC-1562 AC1NQXZW AC1Q6O6X AR-1J6939 BB_NC-2566 C07908 C23H31NO7 CHEMBL1456 CID5281078 CellCept CellCept, RS 61443, TM-MMF, Mycophenolate mofetil Cellcept Cellcept (TN) D00752 DB00688 HMS2090A03 | HSDB 7436 I01-0898 I06-1947 LS-172272 LS-75572 ME-MPA MMF MMF CellCept(TM) MolPort-000-883-800 Munoloc Mycophenolate mofetil (JAN/USAN) Mycophenolic acid morpholinoethyl ester Mycophenylate mofetil NCGC00159459-02 NCGC00159459-03 NSC724229 R-99 RS 61443 RS-61443 RS-61443-190 S1501_Selleck TL8000648 TM-MMF UNII-9242ECW6R0 ZINC21297660 mycophenolate mofetil | |
| | 33 | | Mycophenolic acid | approved | Phase 3, Phase 2, Phase 1 | 952 | 24280-93-1 | 446541 | (e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid Acide mycophenolique Acido micofenolico Acidum mycophenolicum | Melbex Micofenolico acido Mycophenoic acid Mycophenolate Mycophenolsäure Myfortic |
| | 34 | | rituximab | approved | Phase 2, Phase 3 | 1692 | 174722-31-7 | 10201696 | AntiCD20 IDEC-102 IDEC-C2B8 | Ig gamma-1 chain C region MabThera Mabthera Rituxan rituximab |
| | 35 | | Lidocaine | approved, vet_approved | Phase 2, Phase 3 | 1317 | 137-58-6 | 3676 | .alpha.-(Diethylamino)-2,6-acetoxylidide .alpha.-Diethylamino-2,6-dimethylacetanilide .alpha.-Diethylaminoaceto-2,6-xylidide .omega.-Diethylamino-2,6-dimethylacetanilide 137-58-6 2-(Diethylamino)-2',6'-acetoxylidide 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide 2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide 2-Diethylamino-N-(2,6-dimethylphenyl)acetamide 4-12-00-02538 (Beilstein Handbook Reference) 6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE)) 6108-05-0 (mono-hydrochloride, mono-hydrate) 73-78-9 (mono-hydrochloride) AB00053581 AC-10282 AC1L1GGQ AC1Q2Z7J AKOS001026768 ARONIS23855 After Burn Double Strength Gel After Burn Double Strength Spray After Burn Gel After Burn Spray Alphacaine Anestacon Anestacon Jelly BIDD:GT0342 BPBio1_000197 BRD-K52662033-001-02-6 BRD-K52662033-003-05-5 BRN 2215784 BSPBio_000179 BSPBio_001359 BSPBio_003004 Bio-0767 Bio1_000379 Bio1_000868 Bio1_001357 Bio2_000079 Bio2_000559 C07073 C14H22N2O CAS-73-78-9 CDS1_000283 CHEBI:6456 CHEMBL79 CID3676 CPD000058189 Cappicaine Cito optadren Cuivasil D00358 DB00281 Dalcaine Dentipatch Dentipatch (TN) DermaFlex Diethylaminoaceto-2,6-xylidide Dilocaine DivK1c_000174 DivK1c_001323 Duncaine EINECS 205-302-8 ELA-Max EMBOLEX Emla Emla Cream Esracaine FT-0082378 Gravocain HMS1791D21 HMS1989D21 HMS2051C21 HMS2089E15 HMS548M19 HSDB 3350 I01-2704 IDI1_000174 IDI1_033829 Isicaina Isicaine Jetocaine KBio1_000174 KBio2_000079 KBio2_001598 KBio2_002647 KBio2_004166 KBio2_005215 KBio2_006734 KBio3_000157 KBio3_000158 KBio3_002224 KBioGR_000079 KBioGR_000599 KBioSS_000079 KBioSS_001598 L-Caine L0156 L1026_SIGMA L7757_SIGMA LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE) LIDOPEN LQZ | LS-805 Lanabiotic Leostesin Lida-Mantle Lidocaina Lidocaina [INN-Spanish] Lidocaine (JP15/USP/INN) Lidocaine (VAN) Lidocaine Carbonate Lidocaine Hydrocarbonate Lidocaine Monohydrochloride Lidocaine [USAN:INN:JAN] Lidocainum Lidocainum [INN-Latin] Lidocaton Lidoderm Lidoject-1 Lidoject-2 Lignocaine Lignocainum Lingocaine Lopac-L-5647 Lopac0_000669 MLS000069724 MLS000758263 MLS001074177 Maricaine Maybridge1_002571 MolPort-001-783-478 N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide NCGC00015611-01 NCGC00015611-02 NCGC00015611-03 NCGC00015611-04 NCGC00015611-14 NCGC00022176-05 NCGC00022176-06 NCGC00022176-07 NCGC00022176-08 NCGC00022176-09 NINDS_000174 NSC 40030 NSC40030 Norwood Sunburn Spray Octocaine Octocaine-100 Octocaine-50 Prestwick0_000050 Prestwick1_000050 Prestwick2_000050 Prestwick3_000050 Remicaine Rocephin Kit Rucaina S1357_Selleck SAM001247018 SMR000058189 SPBio_001525 SPBio_002100 STK552033 Solarcaine Solarcaine aloe extra burn relief cream Solcain Spectrum2_001343 Spectrum3_001392 Spectrum4_000070 Spectrum5_001549 Spectrum_001118 UNII-98PI200987 WLN: 2N2 & 1VMR B1 F1 Xilina Xilocaina Xilocaina [Italian] Xllina Xycaine Xylestesin Xylesthesin Xylocain Xylocaine Xylocaine (TN) Xylocaine 5% Spinal Xylocaine CO2 Xylocaine Dental Ointment Xylocaine Endotracheal Xylocaine Test Dose Xylocaine Viscous Xylocaine-MPF Xylocaine-MPF with Glucose Xylocaine-Mpf Xylocaine-Mpf with Glucose Xylocard Xylocitin Xyloneural (free base) Xylotox Zilactin-L Zingo alfa-Dietilamino-2,6-dimetilacetanilide alfa-Dietilamino-2,6-dimetilacetanilide [Italian] alpha-Diethylamino-2,6-dimethylacetanilide alpha-diethylamino-2,6-dimethylacetanilide lidocaine nchembio.65-comp16 α-diethylamino-2,6-dimethylacetanilide | |
| | 36 | | Methocarbamol | approved, vet_approved | Phase 3, Phase 2 | 16 | 532-03-6 | 4107 | (RS)-2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate Delaxin Methocarbamol | Methocarbamolum Metocarbamol Metocarbamolo Méthocarbamol Robaxin |
| | 37 | | Omeprazole | approved, investigational, vet_approved | Phase 3 | 348 | 73590-58-6 | 4594 | ( -)-Omeprazole (-)-Omeprazole (S)-(-)-Omeprazole (S)-Omeprazole 119141-89-8 131959-78-9 172964-80-6 2,3,5-Trimethylpyridine/Omeprazole 2-(((3,5-Dimethyl-4-methoxy-2-pyridyl)methyl)sulfinyl)-5-methoxy-1H-benzimidazole 2-({[3,5-dimethyl-4-(methyloxy)pyridin-2-yl]methyl}sulfinyl)-5-(methyloxy)-1H-benzimidazole 5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole 5-Methoxy-2[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole 6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole 73590-58-6 AC-401 AC1L1IIJ AGI-010 AKOS005066653 AULCER Antra Antra MUPS Audazol Aulcer Axagon BIDD:GT0189 BPBio1_000425 BRD-A55962179-001-04-9 BSPBio_000385 Belmazol Bio-0888 C07324 CAS-73590-58-6 CCRIS 7099 CHEBI:519601 CHEBI:7772 CHEMBL1503 CID4594 CPD000058847 Ceprandal D00455 DB00338 DB00736 DM-3458 Danlox Demeprazol Desec Dizprazol Dudencer Elgam Emeproton Emilok Epirazole Erbolin Esomeprazole Esomperazole Esopral Exter Gasec Gastrimut Gastroloc Gibancer H 168-68 H 168/68 H-168/68 H168/68 HMS1528I05 HMS1569D07 HMS2052G17 HMS2090E16 HMS2090F11 HSDB 3575 I06-0705 IDI1_032523 Indurgan Inhibitron Inhipump LS-7629 Lensor Logastric Lomac Losec Losec, Omesec, Prilosec, Zegerid, Omeprazole Lucen MLS000069373 MLS001076112 MLS001424148 Maybridge4_002645 Mepral Miol Miracid MolPort-003-666-741 MolPort-003-807-515 MolPort-003-849-702 Mopral Morecon NCGC00016925-01 | NCGC00016925-02 NCGC00021522-03 NCGC00021522-04 NCGC00021522-05 Nexiam Nexium Nexium IV Nilsec Nopramin Nuclosina O0359 O104_SIGMA OMEP OMP OMZ Ocid Olexin Olit Omapren Omebeta Omebeta 20 Omed Omegast Omepradex Omepral Omeprazol Omeprazol [INN-Spanish] Omeprazole Omeprazole (JAN/USP/INN) Omeprazole Pellets Omeprazole [USAN:INN:BAN:JAN] Omeprazole delayed-release Omeprazole magnesium Omeprazolum Omeprazolum [INN-Latin] Omeprazon Omeprazone Omeprol Omesek Omez Omezol Omezolan Omid Omisec Omizac Ompanyt Ortanol Osiren Ozoken Paprazol Parizac Pepticum Pepticus Peptilcer Prazentol Prazidec Prazolit Prestwick0_000493 Prestwick1_000493 Prestwick2_000493 Prestwick3_000493 Prestwick_808 Prilosec Prilosec (TN) Prilosec OTC Procelac Proclor Prysma Ramezol Regulacid Result S1389_Selleck SAM001246900 SAN-15 SMR000058847 SPBio_002306 STK623746 Sanamidol Secrepina TL8005099 Tedec Ulceral UNII-KG60484QX9 UPCMLD-DP075 UPCMLD-DP075:001 Ulceral Ulcesep Ulcometion Ulcozol Ulcsep Ulsen Ultop Ulzol Victrix Zefxon Zegerid Zepral Zimor Zoltum esomeprazol omeprazole |
| | 38 | | Acetylcholine | approved | Phase 3, Phase 2 | 805 | 51-84-3 | 187 | ACh Acetyl choline ion Acetylcholine Chloride Acetylcholine cation | Acetylcholinium: acetyl-Choline Choline acetate Choline acetate (ester) O-Acetylcholine acetylcholine chloride | |
| | 39 | | Imiquimod | approved, investigational | Phase 3 | 140 | 99011-02-6 | 57469 | 1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine 1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine 1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine 1-isobutyl-1H-imidazo(4,5-c)quinolin-4-amine 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine 3M Brand of Imiquimod 4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline 4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline 99011-02-6 AC-529 AC1L1N2I AC1Q4YO9 Aldara Aldara (TN) Aldara, Imiquimod BB_SC-2107 BIDD:GT0859 Beselna C056493 CHEBI:36704 CHEMBL1282 CID57469 D02500 DB00724 DZ-2636 FT-0080222 HMS2090M14 | I06-0624 I06-2289 I0747 I5159_SIGMA IMIQUIMOD Imiquimod Imiquimod (JAN/USAN/INN) Imiquimod [USAN:INN] Imiquimod acetate Imiquimodum LS-178395 MLS000083577 MTD-39 MolPort-002-507-845 NCGC00070736-02 NSC369100 R 837 R-837 S 26308 S-26308 S1211_Selleck SMR000048307 STK583860 TL8006059 TMX-101 UNII-P1QW714R7M ZINC19632912 Zartra Zyclara imiquimod |
| | 40 | | Domperidone | approved, investigational, vet_approved | Phase 3 | 49 | 57808-66-9 | 3151 | 1-(3-(4-(5-chloro-2-oxo-2,3-Dihydrobenzo[D]imidazol-1-yl)piperidin-1-yl)propyl)-1H-benzo[D]imidazol-2(3H)-one 4-(5-Chloro-2-oxo-1-benzimidazolinyl)-1-[3-(2-oxobenzimidazolinyl)propyl]piperidine 5-24-02-00402 (Beilstein Handbook Reference) 5-Chloro-1-(1-(3-(2-oxo-1-benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone 5-Chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]- 1,3-dihydro-2H-benzimidazol-2-one 5-Chloro-1-[1-[3-(2-oxo-1-benzimidazolinyl)propyl]-4-piperidyl]-2-benzimidazolinone 5-chloro-1-(1-(3-(2-oxo-1-Benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone 5-chloro-1-(1-(3-(2-oxo-2,3-Dihydrobenzo[D]imidazol-1-yl)propyl)piperidin-4-yl)-1H-benzo[D]imidazol-2(3H)-one 5-chloro-1-(1-(3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl)-4-piperidinyl)-1,3-dihydro-2H-benzimidazol-2-one 5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one 5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-propyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one 57808-66-9 6-chloro-3-[1-[3-(2-oxo-3H-benzimidazol-1-yl)propyl]piperidin-4-yl]-1H-benzimidazol-2-one 83898-65-1 (maleate (1:1)) 99497-03-7 (maleate) AB00052423 AC-2037 AC1L1FAB BPBio1_000620 BPBio1_001185 BRD-K38305202-001-02-6 BRN 0903774 BSPBio_002350 Biomol-NT_000022 C22H24ClN5O2 CHEBI:31515 CHEBI:464745 CHEMBL219916 CID3151 D-122 D01745 D122_SIGMA DB01184 DivK1c_006921 Domperidon Domperidona Domperidona [INN-Spanish] Domperidone (JAN/USAN/INN) Domperidone [USAN:BAN:INN:JAN] Domperidonum Domperidonum [INN-Latin] EINECS 260-968-7 EU-0100427 HMS1922N04 HMS2089C14 HMS2093N22 HS-0067 I01-0054 I14-14161 KBio1_001865 KBio2_000871 | KBio2_003439 KBio2_006007 KBioGR_000354 KBioSS_000871 KW 5338 KW-5338 L000230 LS-33301 Lopac-D-122 Lopac0_000427 MLS000859942 MLS001306482 MLS002222324 Motilium Motilium (TN) NCGC00014670 NCGC00014670-05 NCGC00014670-13 NCGC00015306-01 NCGC00021472-02 NCGC00021472-03 NCGC00021472-04 NCGC00021472-05 NCGC00021472-06 NCGC00021472-07 NCGC00021472-08 NCGC00097773-01 NCI299589 NCI60_002512 NCIStruc1_001686 NCIStruc2_001819 NSC-299589 NSC299589 Nauzelin Prestwick0_000461 Prestwick1_000461 Prestwick2_000461 Prestwick3_000461 Prestwick_794 R 33,812 R-33,812 R-33812 S2461_Selleck SMR000326802 SPBio_002501 SPECTRUM2300212 STK622843 SpecPlus_000825 Spectrum4_000087 Spectrum_000391 UNII-5587267Z69 domperidone | |
| | 41 | | Lenograstim | approved | Phase 3, Phase 2, Phase 1 | 1220 | 135968-09-1 | | G-CSF (CHO cell derived) Glycosylated recombinant G-CSF Glycosylated recombinant granulocyte colony stimulating factor | Granulocyte colony stimulating factor 3 (CHO cell derived) Granulocyte colony-stimulating factor lenograstim Lenograstim (genetical recombination) Lenograstim rDNA | |
| | 42 | | Dopamine | approved | Phase 3 | 3836 | 51-61-6, 62-31-7 | 681 | (3H)-Dopamine .Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride .alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane 1,2-Benzenediol, 4-(2-aminoethyl)- (9CI) 1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride 1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium 153C5321-5FEE-4B0B-8925-F388F0EEEBD1 2-(3,4-Dihydroxyphenyl)ethylamine 2-(3,4-dihydroxyphenyl)ethylamine 2-benzenediol 3,4-Dihydroxyphenethylamine 3,4-Dihydroxyphenethylamine hydrochloride 3,4-Dihydroxyphenylethylamine 3,4-dihydroxyphenethylamine 3-Hydroxtyramine 3-Hydroxytyramine 3-Hydroxytyramine Hydrobromide 3-Hydroxytyramine hydrochloride 4-(2-Aminoethyl)-1, 4-(2-Aminoethyl)-1,2-benzenediol 4-(2-Aminoethyl)-1,2-bezenediol 4-(2-Aminoethyl)-Pyrocatechol 4-(2-Aminoethyl)benzene-1,2-diol 4-(2-Aminoethyl)catechol 4-(2-Aminoethyl)pyrocatechol 4-(2-Aminoethyl)pyrocatechol hydrochloride 4-(2-aminoethyl)-pyrocatechol 50444-17-2 51-61-6 62-31-7 (HYDROCHLORIDE) AC1L19S5 AC1Q54AX AC1Q54AY AKOS003790978 ASL 279 BIDD:ER0506 BPBio1_001123 BSPBio_001932 Biomol-NT_000001 C03758 CHEBI:18243 CHEMBL59 CID681 D07870 DB00988 Deoxyepinephrine DivK1c_000780 Dopamin Dopamina Dopamina [INN-Spanish] Dopamine Dopamine (INN) Dopamine (USAN)(*hydrochloride*) Dopamine [INN:BAN] Dopaminum Dopaminum [INN-Latin] Dopastat Dophamine Dynatra EINECS 200-110-0 HSDB 3068 Hydroxytyramin Hydroxytyramine IDI1_000780 IP 498 Intropin Intropin [*hydrochloride*] KBio1_000780 | KBio2_001492 KBio2_002388 KBio2_002484 KBio2_004060 KBio2_004956 KBio2_005052 KBio2_006628 KBio2_007524 KBio2_007620 KBio3_001152 KBio3_002867 KBio3_002962 KBioGR_001129 KBioGR_002388 KBioGR_002484 KBioSS_001492 KBioSS_002393 KBioSS_002491 KW-3-060 L-DOPAMINE L000232 LDP LS-159 Lopac-H-8502 Lopac0_000586 Medopa (TN) MolPort-001-641-000 NCGC00015519-01 NCGC00015519-08 NCGC00096050-01 NCGC00096050-02 NCGC00096050-03 NCGC00096050-04 NCGC00096050-05 NINDS_000780 NSC 173182 NSC169105 NSC173182 Oprea1_088821 Oxytyramine Pyrocatechol, 4-(2-aminoethyl)- (8CI) Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride Revimine Revivan SPBio_001205 SPECTRUM1505155 ST048774 STK301601 Spectrum2_001023 Spectrum3_000406 Spectrum4_000525 Spectrum5_000945 Spectrum_001012 UNII-VTD58H1Z2X UPCMLD0ENAT5885989:001 a-(3,4-Dihydroxyphenyl)-b-aminoethane alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane cMAP_000036 cMAP_000065 dopamine hydroxytyramine intropin m-Hydroxytyramine hydrochloride nchembio.105-comp9 nchembio.107-comp4 nchembio.284-comp1 nchembio.78-comp16 nchembio.89-comp3 nchembio705-8 nchembio801-comp8 |
| | 43 | | Mesna | approved | Phase 3, Phase 1 | 263 | 3375-50-6 | 598 | 2-Mercaptoethane 2-Mercaptoethanesulfonate 2-Mercaptoethanesulfonic acid 2-mercaptoethanesulfonic acid 2-mercaptoethanesulphonic acid 2-mercaptoethylsulfonate 2-sulfanylethylsulfonate | CoM Coenzima M Coenzym M Coenzyme M HS-CoM reduced CoM reduced coenzyme M β-mercaptoethanesulfonic acid | |
| | 44 | | Macitentan | approved | Phase 3 | 36 | 441798-33-0 | | | | 45 | | Fludarabine | approved | Phase 3, Phase 1, Phase 2 | 1154 | 21679-14-1, 75607-67-9 | 30751 | (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol (2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol 2-F-ARAA 2-F-ara-A 2-Fluoro Ara-A 2-Fluoro-9-beta-D-arabinofuranosyladenine 2-fluoro ARA-A 21679-14-1 9-beta-D-Arabinofuranosyl-2-fluoroadenine 9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine 9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI) AC1LCW8I AC1Q51CF C10H12FN5O4 CCRIS 3382 CHEMBL1568 CID657237 CPD000058874 D07966 EINECS 244-525-5 F-Ara-A FAMP FT-0082766 FaraA Fludara Fludara, Fludarabine | Fludarabina Fludarabina [Spanish] Fludarabine Fludarabine (INN) Fludarabine 5'-monophosphate Fludarabine [INN] Fludarabine monophosphate Fludarabine phosphate Fludarabinum Fludarabinum [Latin] Fludura Fluradosa Fluradosa (TN) HSDB 6964 I14-4978 LS-15061 MLS000028687 NSC 118218 NSC 118218H NSC-118218 S1491_Selleck SAM002548956 SMR000058874 SQ Fludarabine UNII-1X9VK9O1SC UNII-P2K93U8740 ZINC04216238 | |
| | 46 | | Lactulose | approved | Phase 3 | 101 | 4618-18-2 | 11333 | (2S,3R,4S,5R,6R)-2-[(2R,3S,4S,5R)-4,5-dihydroxy-2,5-bis(hydroxymethyl)oxolan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol 4-O-b-D-Galactopyranosyl-D-Fructofuranose 4-O-b-D-Galactopyranosyl-D-fructose 4-O-beta-D-Galactopyranosyl-D-Fructofuranose 4-O-beta-D-Galactopyranosyl-D-fructofuranose 4-O-beta-D-Galactopyranosyl-D-fructose 4-O-beta-delta-Galactopyranosyl-delta-Fructofuranose 4-O-beta-delta-Galactopyranosyl-delta-fructose | Bifiteral Cephulac D-Lactulose Lactulosa Lactulose Lactulosum delta-Lactulose lactulosa lactulosum | |
| | 47 | | Nintedanib | approved | Phase 3 | 116 | 656247-17-5 | 56843413 | | Vargatef methyl (3Z)-3-[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}anilino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylate nintedanib | |
| | 48 | | Vidarabine | approved | Phase 3, Phase 1, Phase 2 | 521 | 24356-66-9 | 32326, 21704 | (+)-Cyclaradine .beta.-Adenosine .beta.-D-Adenosine 1odi 2-(6-AMINO-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol 2946-52-3 2fqy 2gl0 30143-02-3 3080-29-3 3228-71-5 4005-33-8 46946-45-6 46969-16-8 524-69-6 5536-17-4 58-61-7 9-Arabinosyladenine 9-beta-D-Arabinofuranosyl-9H-purin-6-amine 9-beta-D-Arabinofuranosyl-adenine 9-beta-D-Arabinofuranosyladenine 9-beta-D-arabinofuranosyl-adenine 9-β-D-arabinofuranosyl-9H-purin-6-amine 9-β-D-arabinofuranosyladenine A 9251 A0152 A4036_SIGMA A4676_SIGMA A5762_SIGMA A9251_SIGMA AC1L18OL AC1L1U8O AC1L2IWM AC1L2SCM AC1O4WIN AC1O8PY7 AC1Q1ID3 AC1Q4Y1Z AC1Q52XU ADENOSINE, U.S.P. ADN AI3-52413 AI3-52821 AR-1H6029 ARA-A NSC 247519 Ade-Rib Adenine Arabinoside Adenine arabinoside Adenine nucleoside Adenine riboside Adenine xyloside Adenocard Adenocard (TN) Adenocard, Adenosine Adenocor Adenoscan Adenoscan (TN) Adenosin Adenosin [German] Adenosine (JAN/USP) Adenosine [USAN:BAN] Adenosine arabinose Adenosine-8-14C Adensoine Ambap5536-17-4 Ara A Ara-A Ara-ATP Araadenosine Arabinoside Adenine Arabinoside adenine Arabinosyl Adenine Arabinosyl adenine Arabinosyl-adenine Arabinosyladenine Arasena-A Armes Armes (TN) BB_NC-0565 BPBio1_000898 BRN 0624881 BSPBio_000816 BSPBio_001796 BSPBio_002000 Bio1_000437 Bio1_000926 Bio1_001415 Boniton C00212 CAS-5536-17-4 CCRIS 2557 CCRIS 3383 CHEBI:136932 CHEBI:16335 CHEBI:45327 CHEMBL1090 CHEMBL20247 CHEMBL477 CI 673 CI-673 CID102198 CID191 CID21704 CID60961 CID6420052 CID6713976 CPD000471872 Caswell No. 010B D000241 D00045 D06298 DB00640 DivK1c_000191 EINECS 200-389-9 EINECS 217-911-6 EINECS 226-893-9 EU-0100123 FT-0082881 HMS1570I18 HMS1920A13 HMS1921K05 HMS2090F06 HMS2091G13 HMS2092C16 HMS500J13 HSDB 6514 | I01-1121 IDI1_000191 KBio1_000191 KBio2_002418 KBio2_004986 KBio2_007554 KBio3_001296 KBio3_001500 KBioGR_001224 KBioSS_002424 L000094 LS-15059 LS-15085 Lopac0_000123 MEDR-640 MLS000069638 MLS000699527 MLS001066352 MLS001333133 MLS001333134 MLS002153227 MLS002153992 MolPort-001-785-903 MolPort-001-838-229 MolPort-003-666-308 Myocol NCGC00016656-01 NCGC00023673-03 NCGC00023673-04 NCGC00023673-05 NCGC00023673-06 NCGC00023673-07 NCGC00094579-01 NCGC00094579-02 NCGC00094579-03 NCGC00094579-04 NCGC00178869-01 NCGC00179417-01 NCI60_003823 NCI60_037192 NCIOpen2_003303 NCIOpen2_005376 NINDS_000191 NSC 247519 NSC 404241 NSC 627048 NSC 7359 NSC 7652 NSC-404241 NSC247519 NSC404241 NSC627048 NSC70422 NSC7359 NSC7652 NSC80832 NSC87676 NSC91041 Nucleocardyl PDSP1_001036 PDSP2_001020 Pallacor Polyadenosine Polyriboadenosine Prestwick0_000768 Prestwick1_000768 Prestwick2_000768 Prestwick3_000768 Prestwick_983 RAB S1647_Selleck S1784_Selleck SAM002564191 SMP1_000312 SMR000058216 SMR000225041 SMR000471872 SMR001233326 SPBio_001194 SPBio_001491 SPBio_002755 SPECTRUM1500107 SPECTRUM1500609 SR 96225 SR-96225 STK361815 SUN-Y4001 Sandesin Spectrum2_001257 Spectrum2_001336 Spectrum3_000288 Spectrum3_000580 Spectrum4_000782 Spectrum5_001429 Spectrum_001894 Spongoadenosine TL8003749 UNII-3XQD2MEW34 UNII-K72T3FS567 USAF CB-10 V0098 VIRDARABINE Vidarabin Vidarabina Vidarabina [DCIT] Vidarabine Vidarabine (JAN) Vidarabine anhydrous Vidarabinum Vira ATM Vira-A Vira-A, Vidarabine XA Xylosyl A Xylosyladenine ZINC00970363 ZINC02169830 adenine-D-ribose adenosine alpha-Ara A beta-Adenosine beta-Ara A beta-D-Adenosine bmse000061 nchembio.143-comp9 nchembio.186-comp109 nchembio.64-comp4 nchembio706-5 |
| | 49 | | Prednisone | approved, vet_approved | Phase 3, Phase 1 | 1398 | 53-03-2 | 5865 | (1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione (8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione .delta. E .delta.(sup1)-Cortisone .delta.-Cortelan .delta.-Cortisone .delta.-Cortone .delta.-E .delta.1-Cortisone .delta.1-Dehydrocortisone .delta.sone 1,2-Dehydrocortisone 1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione 1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione 1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione 1-Cortisone 1-Dehydrocortisone 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione 17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione 53-03-2 68-59-7 81552_FLUKA AC-11112 AC1L1LB2 AC1Q29EZ ACon0_000082 ACon1_000297 AI3-52939 Adasone Ancortone Apo-Prednisone Apo-prednisone BPBio1_000323 BRD-K85883481-001-04-2 BSPBio_000293 Betapar Bicortone Bio-0649 C07370 C21H26O5 CCRIS 2646 CHEBI:8382 CHEMBL635 CID5865 CPD001227202 Cartancyl Colisone Cortan Cortancyl Cortidelt Cotone DB00635 Dacorten Dacortin Decortancyl Decortin Decortisyl Dehydrocortisone Dekortin Delcortin Dellacort Dellacort A Delta Cortelan Delta E Delta E. Delta-Cortelan Delta-Dome Delta-cortelan Delta-cortisone Delta-cortone Delta-dome Deltacortene Deltacortisone Deltacortone Deltasone Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone Deltison Deltisona Deltisone Deltra Di-Adreson Diadreson EINECS 200-160-3 Econosone Encorton Encortone Enkortolon Enkorton Fernisone Fiasone HMS1568O15 HMS2090J13 HSDB 3168 Hostacortin In-Sone Incocortyl | Juvason Kortancyl LMST02030180 LS-1325 Liquid Pred Lisacort Lodotra MEGxm0_000443 MLS001061265 MLS001304073 MLS001335907 MLS001335908 MLS002154191 MLS002207083 Me-Korti Metacortandracin Meticorten Meticorten (Veterinary) Metrevet (Veterinary) MolPort-001-740-041 NCGC00090766-01 NCGC00090766-02 NCGC00090766-03 NCI-C04897 NCI60_000008 NSC 10023 NSC10023 Nisona Nizon Novoprednisone Nurison Orasone Origen Prednisone P1276 P6254_SIGMA PRD Panafcort Panasol Paracort Parmenison Pehacort Precort Predeltin Prednicen-M Prednicorm Prednicort Prednicot Prednidib Prednilonga Prednison Prednisona Prednisona [INN-Spanish] Prednisone Prednisone Intensol Prednisone [INN:BAN] Prednisonum Prednisonum [INN-Latin] Prednitone Prednizon Prednovister Presone Prestwick0_000077 Prestwick1_000077 Prestwick2_000077 Prestwick3_000077 Prestwick_405 Pronison Pronisone Rectodelt Retrocortine S1622_Selleck SAM002264641 SK-Prednisone SMR000718760 SMR001227202 SPBio_002214 Servisone Sone Sterapred Supercortil U 6020 UNII-VB0R961HZT Ultracorten Ultracortene WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ Winpred Wojtab ZINC03875357 Zenadrid Zenadrid (veterinary) Zenadrid [veterinary] delta cortelan delta(sup 1)-Cortisone delta(sup 1)-Dehydrocortisone delta-1-Cortisone delta-1-Dehydrocortisone delta-Cortisone delta-Cortone | |
| | 50 | | Leuprolide | approved, investigational | Phase 3 | 299 | 53714-56-0 | 3911, 657181 | (D-Leu(6),des-gly-NH2(10),pro-ethylamide(9))-gonadotropin-releasing hormone 5-oxoPro-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-ProNHC2H5 dihydrate 5-oxoprolylhistidyltryptophylseryltyrosylleucylleucyl-n5-(diaminomethylidene)ornithyl-n-ethylprolinamide AC1L1GZK AC1L9B44 AC1Q5OPO AR-1G9354 C07612 CID3911 CID441410 D00989 D08113 Enantone Enantone (TN) I04-0109 L-Pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-L-proline ethylamide L001094 | L002030 Leuprolide Leuprolide acetate Leuprolide acetate (USAN) Leuprorelin Leuprorelin (INN) Leuprorelin acetate (JAN) Leuprorelina Leuproreline Leuprorelinum Lupron (TN) N-[1-[[1-[[1-[[1-[[1-[[1-[[5-(diaminomethylideneamino)-1-[2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide NSC377526 NSC746847 PGlu-his-trp-ser-tyr-D-leu-leu-arg-pro-NHC2H5 PGlu-his-trp-ser-tyr-D-leu-leu-arg-pro-nhet acetic acid leuprolide | |
|
Interventional clinical trials: (show top 50)
(show all 314)
| id | Name | Status | NCT ID | Phase |
|---|
| 1 | Influenza Vaccination in Patients With Scleroderma | Unknown status | NCT01002508 | Phase 4 | | 2 | The Clinical And Subclinical Effects on Arterial Stiffness of Bosentan in Patients With Systemic Sclerosis | Unknown status | NCT02480335 | Phase 4 | | 3 | Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan | Unknown status | NCT01051960 | Phase 4 | | 4 | A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis | Unknown status | NCT01042158 | Phase 4 | | 5 | Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases | Unknown status | NCT01151644 | Phase 4 | | 6 | Bosentan in Systemic Sclerosis | Completed | NCT01395732 | Phase 4 | | 7 | Pulmonary Artery Remodelling With Bosentan | Completed | NCT00595049 | Phase 4 | | 8 | Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon | Completed | NCT00048776 | Phase 4 | | 9 | To Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmonary Arterial Hypertension in Systemic Sclerosis | Recruiting | NCT03053739 | Phase 4 | | 10 | Intraoperative ICG for Systemic Sclerosis | Not yet recruiting | NCT03155464 | Phase 4 | | 11 | Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels | Terminated | NCT00578578 | Phase 4 | | 12 | Comparison of Esophageal and Anorectal Manometry Catheters | Terminated | NCT00204763 | Phase 4 | | 13 | Probiotics in Patients With Moderate-to-severe Distention/ Bloating From Systemic Sclerosis | Withdrawn | NCT01497743 | Phase 4 | | 14 | High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis | Unknown status | NCT00428883 | Phase 2, Phase 3 | | 15 | Effects of Probiotics on Gastrointestinal Symptoms and on the Immune System in Patients With Systemic Sclerosis | Unknown status | NCT02302352 | Phase 3 | | 16 | Serial Night Time Position Splint on Systemic Sclerosis | Unknown status | NCT01586663 | Phase 3 | | 17 | Platelet Gel in Systemic Sclerosis | Unknown status | NCT00463125 | Phase 2, Phase 3 | | 18 | Early Diagnosis of Pulmonary Hypertension in Patients With Inflammatory Rheumatic Connective Tissue Diseases | Unknown status | NCT01387035 | Phase 3 | | 19 | A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon | Unknown status | NCT00577304 | Phase 3 | | 20 | Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms | Unknown status | NCT00934427 | Phase 3 | | 21 | Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY | Completed | NCT01295736 | Phase 3 | | 22 | Efficacy and Safety Study of GB-0998 for Treatment of Systemic Sclerosis | Completed | NCT00348296 | Phase 3 | | 23 | High Dose Cyclophosphamide for Treatment of Scleroderma | Completed | NCT00501995 | Phase 3 | | 24 | Effectiveness and Safety of Lidocaine for Scleroderma | Completed | NCT00740285 | Phase 2, Phase 3 | | 25 | Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients | Completed | NCT01474109 | Phase 3 | | 26 | Gastroesophageal Reflux Treatment in Scleroderma | Completed | NCT01878526 | Phase 3 | | 27 | Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma | Completed | NCT00704665 | Phase 3 | | 28 | Scleroderma: Cyclophosphamide or Transplantation (SCOT) | Completed | NCT00114530 | Phase 2, Phase 3 | | 29 | Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis | Completed | NCT01347008 | Phase 3 | | 30 | Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome | Completed | NCT02165111 | Phase 3 | | 31 | Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With Scleroderma | Completed | NCT00077584 | Phase 3 | | 32 | Scleroderma Lung Disease | Completed | NCT00004563 | Phase 3 | | 33 | Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma | Completed | NCT00070590 | Phase 2, Phase 3 | | 34 | Effect of Rosuvastatin on Systemic Sclerosis-related Pulmonary Hypertension | Completed | NCT00984932 | Phase 3 | | 35 | A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma | Completed | NCT01117298 | Phase 3 | | 36 | A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma | Completed | NCT01553981 | Phase 3 | | 37 | Bosentan in Digital Ulcers | Completed | NCT00319696 | Phase 3 | | 38 | Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma | Completed | NCT00626665 | Phase 3 | | 39 | A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis | Completed | NCT01532869 | Phase 3 | | 40 | Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis | Completed | NCT00004786 | Phase 3 | | 41 | Open-label Study With Bosentan in Interstitial Lung Disease | Completed | NCT00319033 | Phase 2, Phase 3 | | 42 | Imiquimod in Children With Plaque Morphea | Completed | NCT00147771 | Phase 3 | | 43 | A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon | Completed | NCT00498615 | Phase 3 | | 44 | Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon | Completed | NCT00266669 | Phase 3 | | 45 | Lab Study of MQX-503 in Treatment of Raynaud's | Completed | NCT00253331 | Phase 2, Phase 3 | | 46 | Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon | Completed | NCT00419419 | Phase 3 | | 47 | Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome | Completed | NCT00025818 | Phase 3 | | 48 | "As Required" Oral Sildenafil in Raynaud's Phenomenon | Completed | NCT02050360 | Phase 2, Phase 3 | | 49 | Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension | Completed | NCT00080457 | Phase 3 | | 50 | Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial | Recruiting | NCT01445821 | Phase 3 |
Inferred drug relations via UMLS68/NDF-RT46:
|
